Results 171 to 180 of about 634,915 (204)

Abstract 2336: Pan-cancer analysis of NAMPT inhibitors reveals unique sensitivities to multiple NAMPT inhibitors in several cancer types

Cancer Research, 2022
Abstract Nicotinamide phosphoribosyltransferase (NAMPT) plays a critical role in cellular metabolism and as such has been an active target for cancer drug therapy. NAMPT inhibition, via small molecule NAMPT inhibitors, disrupts cellular energy metabolism as well as other NAD+-dependent processes and has been shown to suppress cancer cell
Jenny J. Hong, Martina S. McDermott, Jewel K. Ng, Prita Pandya, Dennis J. Slamon   +4 more
openaire   +1 more source

Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors as Therapeutics: Rationales, Controversies, Clinical Experience

Current Drug Targets, 2013
Nicotinamide adenine dinucleotide (NAD+) biosynthesis from nicotinamide is used by mammalian cells to replenish their NAD+ stores and to avoid unwanted nicotinamide accumulation. Pharmacological inhibition of nicotinamide phosphoribosyltransferase (NAMPT), the key enzyme in this biosynthetic pathway, almost invariably leads to intracellular NAD ...
MONTECUCCO, FABRIZIO, CEA, MICHELE, Bauer I, SONCINI, DEBORA, CAFFA, IRENE, Lasigliè D, Nahimana A, UCCELLI, ANTONIO, BRUZZONE, SANTINA, NENCIONI, ALESSIO   +9 more
openaire   +2 more sources

NAMPT Is A Novel Inhibitor of Vascular Calcification in Chronic Kidney Disease

Arteriosclerosis, Thrombosis, and Vascular Biology
BACKGROUND: Vascular calcification is very common in patients with chronic kidney disease and contributes to the increased risk of cardiovascular events. NAMPT (nicotinamide phosphoribosyltransferase), the rate-limiting enzyme in the salvage pathway of nicotinamide adenine dinucleotide, has been shown to exert an antiaging ...
Qianqian Dong, Lihe Lu, Xiuli Zhang, Liyun Feng, Li Li, Hao Liu, An Chen, Zirong Lan, Yuanzhi Ye, Jiahui Zhu, Xiaoyu Liu, Yining Li, Qingchun Liang, Jianyun Yan   +13 more
openaire   +2 more sources

Dual-targeted NAMPT inhibitors as a progressive strategy for cancer therapy

Bioorganic Chemistry
In mammals, nicotinamide phosphoribosyltransferase (NAMPT) is a crucial enzyme in the nicotinamide adenine dinucleotide (NAD+) synthesis pathway catalyzing the condensation of nicotinamide (NAM) with 5-phosphoribosyl-1-pyrophosphate (PRPP) to produce nicotinamide mononucleotide (NMN).
Günindi, Habibe Beyza, Ozgencil, FİKRİYE, Eren, GÖKÇEN   +2 more
openaire   +3 more sources

Synthesis and Evaluation of Reactive Oxygen Species Sensitive Prodrugs of a NAMPT Inhibitor FK866

Molecules, 2023
Zili Xu
exaly  

A Novel Synthesis of the NAMPT Inhibitor FK866

Analytical Chemistry: A Journal, 2023
openaire   +1 more source

NAMPT INHIBITORS

2013
CLARK RICHARD F, SORENSEN BRYAN, OSUMA AUGUSTINE T, FREY ROBIN, LONGENECKER KENTON, DOHERTY GEORGE, CURTIN MICHAEL L, MICHAELIDES MICHAEL R, SWEIS RAMZI F, PLIUSHCHEV MARINA A, JUDD ANDY, HANSEN TODD M, HEYMAN HOWARD R   +12 more
  +14 more sources

An NAMPT Inhibitor Decreases NAMPT Capture by an Antibody Directed against the 5-Phosphoribosyl-1-Pyrophosphate-Binding Loop: A Rational for an NAMPT Occupancy Assay

Abstract Nicotinamide phosphoribosyltransferase (NAMPT) catalyzes the rate-limiting step of nicotinamide adenine dinucleotide (NAD) biosynthesis. NAMPT inhibitors (NAMPTi) have been shown to be NAMPT substrates. The resulting NAMPTi-phosphoribose (RP) adduct binds tightly to NAMPT and inhibits the enzyme.
Maysoun Shomali, Sandrine Hilairet, Marianne Duhamel, Frederico Nardi, Thomas Bertrand, Magali Mathieu, Rosalia Arrebola, Geraldine Penarier, Samir Jegham, Jerome Arigon, Sylvie Cosnier, Monsif Bouaboula   +11 more
openaire   +1 more source

Involvement of p53 in the cytotoxic activity of the NAMPT inhibitor FK866 in myeloid leukemic cells†‡

International Journal of Cancer, 2013
Karl Heinrich Welte, Dirk Reinhardt, Basant Kumar Thakur   +2 more
exaly  

Discovery of -3-(pyridin-3-yl)acrylamide-derived sulfamides as potent nicotinamide phosphoribosyltransferase (NAMPT) inhibitors for the potential treatment of cancer

Bioorganic and Medicinal Chemistry Letters, 2019
Sheng Jiang, Hequan Yao, Xiaoxing Wu
exaly